SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX) announced today that it has completed enrollment in study
C119, a second Phase 3 clinical trial of its lead product candidate
NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy
(HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral
neuropathic pain. Previously completed Phase 3 trials demonstrated that a
single, 30- or 60-minute treatment with NGX-4010 applied directly to the
site of pain may provide pain relief for up to three months. C119 is a
randomized, double-blind, controlled study that has enrolled over 480
patients at study sites in the United States, the United Kingdom, Australia
and Canada.

"We believe that completion of enrollment in our C119 study marks a
significant milestone in our NGX-4010 development program in HIV-DSP. We
are currently in the follow-up phase of the study and expect to be able to
provide top-line results near the end of the first quarter of 2008,"
commented Dr. Jeffery Tobias, Chief Medical Officer. "HIV-DSP is an
important and underserved problem in patients with HIV/AIDS. There are
currently no approved therapies for this indication. With the completion of
enrollment in study C119, we are moving closer to our goal of providing an
effective treatment for this patient population."

The study protocol for study C119 evaluates the effect of a single, 30-
or 60-minute treatment with NGX-4010 or a low-concentration control patch
applied directly to the patient's site of pain. NGX-4010 is administered by
a physician during an in-office procedure. After 30 or 60 minutes, the
study patch is removed and the patient's response to treatment is evaluated
during the subsequent 12-week study period.

Anthony A. DiTonno, President and CEO, commented, "I am very pleased
with our ability to complete the enrollment of this study ahead of plan.
When we completed our initial public offering earlier this year, we
indicated that we would file a new drug application (NDA) with the Food and
Drug Administration (FDA) in the second half of 2008. Completion of
enrollment in this study, on top of our three already completed successful
Phase 3 trials, increases our confidence that we can meet this goal."

NeurogesX has successfully completed two Phase 3 studies in
postherpetic neuralgia (PHN) and one in HIV-DSP. NGX-4010 has been granted
orphan status and has received fast track designation from the FDA for
HIV-DSP. NeurogesX believes that it is on track to file for marketing
approval in the European Union before the end of 2007 for a broad
indication of peripheral neuropathic pain. The Company is currently
evaluating various regulatory filing strategies in the United States in
order to most efficiently seek FDA approval of both the PHN and HIV-DSP
indications, and believes that it will be able to submit a new drug
application with the FDA in 2008.

About PHN and HIV-DSP

PHN is a painful condition affecting sensory nerve fibers. It is a
complication of shingles, a second outbreak of the varicella-zoster virus,
which initially causes chickenpox. Following an initial infection, some of
the virus can remain dormant in nerve cells. Years later, age, illness,
stress, medications or other factors that are not well understood can lead
to reactivation of the virus. The rash and blisters associated with
shingles usually heal within six weeks, but some people continue to
experience pain for years thereafter. This pain is known as postherpetic
neuralgia. PHN may occur in almost any area, but is especially common on
the torso.

HIV-DSP is caused primarily by three factors: direct activation of
cells known as sensory neurons by the HIV virus, the immune system's fight
against the infection, and the drugs administered to treat HIV. Painful
HIV-DSP is characterized by significant pain in the feet and hands.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on
developing novel pain management therapies. Its initial focus is on chronic
peripheral neuropathic pain, including PHN, painful HIV-DSP and painful
diabetic neuropathy. NeurogesX' late stage product portfolio is led by its
product candidate NGX-4010, a dermal patch designed to manage pain
associated with peripheral neuropathic pain conditions, that the company
believes offers significant advantages over other pain therapies. Three
Phase 3 clinical trials with NGX-4010 have been completed and have met
their primary endpoints, two in PHN and one in HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements relating to the
successful completion of the C119 clinical trial with respect to NeurogesX'
lead product candidate, NGX-4010, including the timing of announcement of
results from such trial; filing for regulatory approval and the timing of
such filings; the ability to obtain approval for and commercialize
NGX-4010. Such statements are based on management's current expectations,
but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, past results of clinical
trials may not be indicative of future clinical trials results; NeurogesX'
product candidate may have unexpected adverse side effects or inadequate
therapeutic efficacy; positive results in clinical trials may not be
sufficient to obtain FDA or European regulatory approval; physician or
patient reluctance to use NGX-4010, if approved, or the inability of
physicians to obtain sufficient reimbursement for such procedures;
potential alternative therapies; maintaining adequate patent or trade
secret protection without violating the intellectual property rights of
others; and other difficulties or delays in clinical development, obtaining
regulatory approval, market acceptance and commercialization of NGX-4010
and the advantages of NGX-4010 over other pain therapies. For further
information regarding these and other risks related to NeurogesX' business,
investors should consult NeurogesX' filings with the Securities and
Exchange Commission.

(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...

(Date:9/27/2017)... , Sept. 27, 2017 Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...

(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...

(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...

(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...

(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...